This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Carver, B. S. Articles by Sheinfeld, J. Search for Related Content PubMed PubMed Citation Articles by Carver, B. S. Articles by Sheinfeld, J. Related Articles Related Editorial Social Bookmarking                            What's this?

Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection

Brett S. Carver, Bobby Shayegan, Scott Eggener, Jason Stasi, Robert J. Motzer, George J. Bosl, Joel Sheinfeld

From the Department of Urology and Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY

Address reprint requests to Brett S. Carver, MD, Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, 353 E 68th St, New York, NY 10021; e-mail: carverb{at}mskcc.org

Introduction Modified template retroperitoneal lymph node dissections (RPLND) have become increasing applied in the postchemotherapy (PC) setting. We evaluated our experience with PC-RPLND to determine the incidence of disease extending outside the boundaries of a modified PC-RPLND.

Patients and Methods From 1989 through 2003, a total of 532 men underwent PC-RPLND for metastatic nonseminomatous germ cell tumor (NSGCT). Of these, 269 (51%) had either viable germ cell tumor (GCT) or teratoma present in the RPLND specimen. After Institutional Review Board approval, clinical and pathologic data were obtained from our prospective surgical database. The incidence of retroperitoneal disease outside the boundaries of five modified templates was reported for the presence of viable GCT or teratoma.

Results Of the 269 patients with viable GCT or teratoma, 20 to 86 (7% to 32%) patients had evidence of extratemplate retroperitoneal disease, depending on the boundaries of the modified template. There was no difference in the histologic distribution for patients with disease confined to or outside of the modified templates. Despite the absence of preoperative radiographic evidence of disease outside the boundaries of the Testicular Tumor Study Group template, the incidence of extratemplate metastasis for men with residual retroperitoneal masses less than 1, 1 to 2, 2 to 5, and more than 5 cm was two of 24 (8%), seven of 38 (18%), 27 of 92 (29%), and 14 of 55 (25%), respectively.

Conclusion Our data suggest a bilateral RPLND is a prudent approach for the management of men with metastatic NSGCT after chemotherapy, given that at least 7% to 32% of men will have teratoma or viable GCT outside the boundaries of a modified template.

Supported in part by the Craig Tifford Foundation.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Editorial

• Redefining the Refined Retroperitoneal Lymph Node Dissection in Testis Cancer: A SWOT Analysis of Nonrandomized Data
  Marc B. Garnick
  JCO 2007 25: 4337-4338 [Full Text]

This article has been cited by other articles:

				H. J. Lavery, R. R. Bahnson, D. S. Sharp, and K. S. Pohar Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors Therapeutic Advances in Urology, October 1, 2009; 1(4): 199 - 207. [Abstract] [PDF]

				D. S. Sharp, B. S. Carver, S. E. Eggener, G. V. Kondagunta, R. J. Motzer, G. J. Bosl, and J. Sheinfeld Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor J. Clin. Oncol., December 1, 2008; 26(34): 5524 - 5529. [Abstract] [Full Text] [PDF]

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				M. B. Garnick Redefining the Refined Retroperitoneal Lymph Node Dissection in Testis Cancer: A SWOT Analysis of Nonrandomized Data J. Clin. Oncol., October 1, 2007; 25(28): 4337 - 4338. [Full Text] [PDF]